The Medical Research Institute of the Hospital La Fe

Address Av. Fernando Abril Martorell, nº 106
Torre A, 7ª. 46026 Valencia
Platforms ATMP & Biological, Biomarkers, Imaging & Tracing

The Medical Research Institute of Hospital La Fe (HULAFE, is a non-profit organisation that carries out the scientific and research policy of the “La Fe” Health Department. The research of excellence carried out at the HULAFE is patient-oriented and was accredited as a “Health Research Institute” by the Spanish Ministry of Science and Innovation in 2009.

The HULAFE offers scientific and technological services and has more than 10,000 m2 of clinical and research laboratories to undertake research programmes based on state-of-the-art biomedical science, which aim to promote our five priority research areas:

1. Organ Transplants, Artificial Tissues and Implants
2. Cancer
3. Genetics, Genomics and Translational Research underlying disease mechanisms
4. Experimental-Clinical Research in Neurology
5. Clinical, Epidemiological and Pharmacological Research
6. Technological Research in Biomedicine and Health

The HULAFE comprises multidisciplinary and complementary research groups with consolidated expertise in cellular and molecular biology, cell culture, functional analysis imaging, “omics” and clinical research. All groups have a solid scientific background, critical mass, organization and sustainability by competitive national and international calls as well successful interactions with the private sector.

The accredited research groups have a unique combination of biochemists, cell and molecular biologists, clinicians, surgeons and patient care personnel capable to tackle a complex research objective in the biomedical sector. The research groups included in this Executive Summary are part of “Accredited Research Groups” according to HULAFE corporative and established standards integrating junior and senior physician and basic researchers with an outstanding track record of publications and translational oriented research.

Institutes' Omics Technologies

Click on an item to find out more


  • High performance liquid chromatography (HPLC,UHPLC)
  • LC-MS
  • Desorption electrospray ionization (DESI)
  • Untargeted metabolomics assays
  • Targeted metabolomic assays
  • Research
  • Biomarkers discovery and development
  • Diagnostics and personalised disease profiling
  • Disease processes research
  • Responses to environment


Collaboration with industry where the institute collaborated with Metabolomics expertise (in the last 5 years) <10
% of TIME involved in technology/methods development/innovation/intellectual property related to Metabolomics 70%

Track record

Key opinion leaders
  • Agustín Lahoz PhD (Scientist Director): Biomarkers and precision Medicine
  • Marta Roca PhD (Coordinator of the Analytical platform): Untargeted metabolomic and lipidomic studies
  • Marina Lopez PhD (Technician): targeted metabolomic studies
  • Maribel Alcoriza (collaborator): bioinformatic


  • Proteomics
  • Metabolomics


  • Proteomics
  • Metabolomics


  • Simca
  • Molecular profiling (omics and others)
  • Expertise in clinical design of experiments, clinical statistics
  • Metadata (patient/sample information)
  • Methods and policies for information infrastructure, including privacy and security


  • Metabolites annotation
  • Data integration (“Systems biology”)
  • Drug-target interaction analysis
  • Drug screening analysis
  • Development of new algorithms, e.g. new decision algorithms, new sequence aligners for NGS data, etc.
  • Development of semantic analysis tools
  • Informatics methods to support clinical decisions (diagnostic, predictive tests)


  • Own scripts/software